Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CD2-H82E8 | Human | Biotinylated Human CD52 Protein, His,Avitag™ |  |
|
|
| CD2-H525a | Human | Human CD52 Protein, Fc Tag |  |
|
|
| CD2-H82F3 | Human | Biotinylated Human CD52 Protein, Fc,Avitag™ |  |
|
Anti-Human CD52 MAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Biotinylated Human CD52, His,Avitag (Cat. No. CD2-H82E8) with an affinity constant of 71.8 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Alemtuzumab | LDP-03; GZ-402673 | Approved | Genzyme Corp, Bayer AG | Campath, Lemtrada, MabCampath | United States | Multiple Sclerosis | Genzyme Corp | 2001-05-07 | Myositis, Inclusion Body; Anemia, Sickle Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Leukemia, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Leukemia, Prolymphocytic, T-Cell; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Peritoneal Neoplasms; Lymphoproliferative Disorders; Sezary Syndrome; Bone marrow transplant rejection; Pancytopenia; Multiple Sclerosis; Rejection of organ transplantation; Hodgkin Disease; Myelodysplastic Syndromes; Kidney Diseases; Leukemia-Lymphoma, Adult T-Cell; Graft vs Host Disease; Lymphoma, T-Cell, Peripheral; Multiple Sclerosis, Relapsing-Remitting; Leukemia; Ovarian Neoplasms; Diabetes Mellitus, Type 1; Hematologic Neoplasms; Rejection of renal transplantation | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Alemtuzumab biosimilar (Zhangjiang Biotechnology) | Phase 2 Clinical | Shanghai Zhangjiang Biotechnology Co Ltd | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| ALLO-647 | ALLO-647 | Phase 2 Clinical | Allogene Therapeutics Inc | Lymphoma, B-Cell; Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Lymphoma, Follicular; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Alemtuzumab Biosimilars(Cellectis) | CLLS-52; CLLS52 | Phase 2 Clinical | Cellectis Sa | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| Recombinant anti-CD52 humanized monoclonal antibody (Lanzhou Institute Of Biological Products/Shanghai Taiyin Biotechnology) | Phase 1 Clinical | Lanzhou Institute Of Biological Products Co Ltd, Shanghai Taiyin Biotechnology Co Ltd | Leukemia, B-Cell; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, Prolymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| Alemtuzumab biosimilar(BioXpress) | BX-1523; BXT-1523 | Clinical | Bioxpress Therapeutics Sa | Multiple Sclerosis; Leukemia, B-Cell | Details |
This web search service is supported by Google Inc.
A-Z
